ImmuPharma plc (LON:IMM – Get Free Report) rose 7.5% during mid-day trading on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.87 ($0.05). Approximately 23,430,012 shares traded hands during mid-day trading, an increase of 22% from the average daily volume of 19,205,051 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Price Performance
The business has a 50 day simple moving average of GBX 1.71 and a 200 day simple moving average of GBX 1.72. The company has a market capitalization of £16.76 million, a price-to-earnings ratio of -402.50 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- 3 Best Fintech Stocks for a Portfolio Boost
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What is the FTSE 100 index?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Energy and Oil Stocks Explained
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
